# Persistent nausea on a GLP-1: when to contact the prescriber

Nausea is a recognized side effect, but symptoms that persist, worsen or interfere with fluids deserve a review. Know which symptoms need urgent care.

Canonical: https://velri.co/blog/glp1-nausea-titration-adjustment-what-counts-normal
Publisher: Velri (https://velri.co/about)
Published: 2026-06-27
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Nausea is a recognized side effect of semaglutide treatment. Persistent symptoms, worsening symptoms or difficulty keeping fluids down should be reported to the prescriber. “Common” does not mean something must be endured without review. [1]

## Describe the pattern

The prescriber needs more than a rating of “bad.” Helpful details include:

- When nausea began and whether it followed a prescribed dose change.
- Whether vomiting, diarrhea, constipation or abdominal pain is also present.
- Whether you can eat and keep fluids down.
- Whether the symptoms are improving, recurring or becoming more intense.

Gastrointestinal symptoms often occur during treatment initiation or dose escalation. The nutrition advisory for GLP-1 care emphasizes reviewing symptoms and intake as part of treatment, including when a slower progression may need consideration by the prescriber. [2]

Dose decisions belong with the prescribing professional.

## Eating and drinking may need attention

Large meals can worsen symptoms for some people, while prolonged periods without eating may also be unhelpful. The advisory discusses smaller meals and adequate fluids as options within individualized symptom management. [2]

If nausea is repeatedly preventing food or fluid intake, that is useful clinical information, not a sign that treatment is working especially well.

## Know the symptoms that need faster help

The semaglutide label warns that vomiting or diarrhea can cause dehydration and kidney problems. Severe or persistent abdominal pain, sometimes extending to the back, can signal pancreatitis and requires immediate medical attention. Trouble breathing or swelling of the face, lips, tongue or throat also requires emergency help. [1]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] 
            Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society - PMC
        . https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support